Communiqués Resverlogix Corp. OTC Markets

Actions

RVXCF

CA76128M1086

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:30:00 28/08/2026			Varia. 5j.	Varia. 1 janv.
0,0495 ^USD	-27,42%		-35,55%	-33,29%

14/08	Resverlogix Corp. publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2026	CI
26/06	Transcript : Resverlogix Corp. - Shareholder/Analyst Call

Communiqués

26/06	Resverlogix Announces Voting Results from the 2026 Meeting of Shareholders	NE
19/05	Resverlogix Closes US$2 Million Shares-for-Interest Private Placement	NE
16/05	Resverlogix : Financial Statement Q1 2026	PU
16/05	Resverlogix : MD&A Q1 2026	PU
11/05	Resverlogix Announces One-Year Extension of Debenture	NE
16/04	Resverlogix Corp. Announces Filing of Annual Filings and Revocation of MCTO	NE
11/04	Resverlogix : Annual Information Form 2025	PU
11/04	Resverlogix : Financial Statement Q4 2025	PU
02/04	Resverlogix Corp. Announces Issuance of MCTO by ASC	NE
01/04	Resverlogix Corp. Provides Bi-Weekly MCTO Status Update	NE
18/03	Resverlogix Announces Delay in Filing of Annual Financial Statements, AIF, and MD&A	NE
19/02	Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement	NE
18/11	Resverlogix Appoints Bradley Glass to Board of Directors	NE
14/11	Resverlogix : MD&A Q3 2025	PU
14/11	Resverlogix : Financial Statement September 30, 2025	PU
14/08/25	Resverlogix : MD&A Q2 2025	PU
30/06/25	Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders	NE
23/05/25	Resverlogix : Annual Meeting of Shareholders - Notice and Access	PU
14/05/25	Resverlogix : Financial Statement Q1 2025	PU
14/05/25	Resverlogix : MD&A Q1 2025	PU
01/04/25	Resverlogix : MD&A Q4 2024	PU
01/04/25	Resverlogix : Financial Statement Q4 2024	PU
13/11/24	Resverlogix : Financial Statement Q3 2024	PU
13/11/24	Resverlogix : MD&A Q3 2024	PU
03/09/24	Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024	NE